Frontiers in Cardiovascular Medicine最新文献

{"title":"The role of oxidative stress in modulating mortality risk across the hypertension control cascade.","authors":"Weihao Liu, Chunyang Hou, Hongjie Wang, Hao Du, Xianyu Dai, Yu Jiang, Yuchuan Hou","doi":"10.3389/fcvm.2025.1621911","DOIUrl":"10.3389/fcvm.2025.1621911","url":null,"abstract":"<p><strong>Background: </strong>The role of oxidative stress in hypertensive populations has not yet been fully elucidated. This study examines the association between the Oxidative Balance Score (OBS) and all-cause and cardiovascular mortality under different hypertension control cascade outcomes while assessing mediation by low-grade systemic inflammation and multi-organ function.</p><p><strong>Methods: </strong>This cohort study analyzed 1999-2018 NHANES data, with mortality outcomes from the National Death Index (NDI). It encompassed U.S. adults with hypertension. OBS consists of 20 nutrition and lifestyle factors. Low-grade systemic inflammation (NLR, SIRI) and multi-organ function (eGFR, UACR, FIB-4 index, SUA) were examined as potential mediators. Statistical analyses included Kaplan-Meier analysis, Cox models, restricted cubic splines (RCS), subgroup analyses, and mediation analysis.</p><p><strong>Results: </strong>Participants in the highest OBS quartile (Q4) exhibited lower all-cause mortality (HR: 0.72; 95% CI: 0.59-0.88; <i>P</i> = 0.001) and cardiovascular mortality (HR: 0.64; 95% CI: 0.42-0.99; <i>P</i> = 0.044) than Q1 after adjusting for confounders. The OBS-mortality association varied by hypertension control status, with greater risk reduction in controlled hypertension (Q4 vs. Q1, HR: 0.43; 95% CI: 0.27-0.69; <i>P</i> < 0.001) than in uncontrolled hypertension (Q4 vs. Q1, HR: 0.82; 95% CI: 0.66-0.87; <i>P</i> < 0.001). A significant interaction was observed between OBS and hypertension control status (<i>P</i> for interaction = 0.017 and 0.026), corroborated by sensitivity analyses (<i>P</i> for interaction = 0.025). Sensitivity analyses confirmed Nutrition-OBS reduced all-cause mortality by 31%, and Lifestyle-OBS decreased cardiovascular mortality by 45%. RCS analyses verified the inverse OBS-mortality relationship, with mediation analysis revealing partial mediation through low-grade systemic inflammation and multi-organ function.</p><p><strong>Conclusions: </strong>A higher OBS is associated with lower all-cause and cardiovascular mortality under different hypertension control cascade outcomes, with a more pronounced effect in controlled hypertension. This relationship is partially mediated through systemic inflammation and multi-organ function.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1621911"},"PeriodicalIF":2.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular disease in North African women: insights from the Middle East African Women CardioVascular Disease (MEA-WCVD) registry.","authors":"Salma Charfeddine, Leila Abid, Sarra Chenik, Iheb Ben Krayen, Oussama Haddar, Aymen Ghrab, Selim Boudiche, Haithem Touati, Oumaima Ayedi, Mohamed Amine Ammar, Manel Ben Halima, Houssem Ben Ayed, Asma Brahim, Faten ElAyech, Emna Allouche, Houssem Thabet, Houaida Mahfoudhi, Taha Yessine Jabloun, Yasmine Ayadi, Alaeddine Ayadi, Ghassen Romdhani, Hassen Gargouri, Oumayma Zidi, Mohamed Ali Guedri, Rami Tlili, Bechir Trabelsi, Selim Hammami, Rim Othmen, Saoussen Antit, Syrine Saidane, Sirine Dardour, Skander Iddir, Elmahdi Kharrat, Anis Cheikhrouhou, Mohamed Derwich, Amal Mrabet, Taha Lassoued, Emna Rekik, Sahar Gmiha, Niez Laribi, Hakim Lamine, Zied Triki, Samir Ayari, Fatma Boujelbene, Essia Boughzela, Hajer Rekik, Ines Ben Ameur, Syrine Abid, Khalil Oueghlani, Abddayem Haggui, Afef Ben Halima, Wejdene Ouechtati, Emna Bennour, Rania Hammami, Mariem Jabeur, Ihsen Zairi, Mariem Drissa, Faouzi Addad, Sami Milouchi, Mohamed Sami Mourali, Hedi Ben Slima, Leila Bezdah, Elyes Neffati, Youssef Ben Ameur, Sondos Kraiem, Salem Kachboura, Ikram Kammoun, Lilia Zakhama, Hassen Lbn Hadj Amor, Khaldoun Ben Hamda, Yosra Messoudi, Nejah Ben Hlima, Rana Dahmani, Habib Gamra, Zied Ibn Elhadj, Hichem Denguir, Chayma Ghorbel, Nizar Mechri, Samia Ernez Hajri, Alexandre Mebazaa, Fedi Ben Dhaou, Maroua Trigui, Wafa Fehri, Salem Abdessalem","doi":"10.3389/fcvm.2025.1577793","DOIUrl":"10.3389/fcvm.2025.1577793","url":null,"abstract":"<p><p>Cardiovascular disease (CVD) is a major health burden worldwide, yet gender-specific data from the Middle East and North Africa (MENA) region remain scarce. The Middle East African Registry of Women with Cardiovascular Disease enrolled adult patients with coronary heart disease (CHD), heart failure (HF), atrial fibrillation (AF), or valvular heart disease (VHD) across Tunisia between May and July 2023. Of 15,366 patients, 37.6% were women. Compared with men, women were older, had lower socioeconomic status, and presented with more obesity, hypertension, diabetes, dyslipidemia, and sedentary lifestyle but smoked less. CHD was less frequent in women, while AF and VHD were more prevalent. Women underwent fewer coronary angiographies and percutaneous interventions, experienced longer delays, and received fewer guideline-based therapies, including dual antiplatelet agents and high-intensity statins. Among HF patients, women more often had preserved ejection fraction and higher hospitalization rates. These results highlight persistent gender inequities in CVD care in Tunisia.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1577793"},"PeriodicalIF":2.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoplasmic reticulum stress in cardiomyopathies: from the unfolded protein response to therapeutic opportunities.","authors":"Yueqing Qiu, Zhenyi Chen, Pingge He, Zhentao Wang","doi":"10.3389/fcvm.2025.1577186","DOIUrl":"10.3389/fcvm.2025.1577186","url":null,"abstract":"<p><p>The endoplasmic reticulum (ER), a central organelle responsible for maintaining protein homeostasis, calcium balance, and lipid metabolism, is essential for cardiovascular integrity. Functional disruption-referred to as endoplasmic reticulum stress (ERS)-has been recognized as a major pathogenic driver across diverse cardiovascular disorders. Under pathological conditions such as hypoxia, nutrient deprivation, or infection, sustained ERS activates the unfolded protein response (UPR). While initially adaptive, prolonged or excessive ERS initiates apoptotic cascades, severely impairing cardiomyocyte metabolism, structure, and survival. This review examines the pivotal contribution of dysregulated ERS to the pathogenesis of various cardiomyopathy subtypes, including dilated, diabetic, hypertrophic, and arrhythmogenic right ventricular forms. We outline how ERS fosters maladaptive cardiac remodeling by promoting cardiomyocyte apoptosis and exacerbating oxidative stress, ultimately leading to heart failure. Special attention is given to the complex crosstalk between ERS-related signaling pathways (e.g., PERK, IRE1α, ATF6) and disease progression, with detailed analysis of key regulatory molecules, pathogenic genetic variants, and epigenetic alterations. Integrating recent advances, we highlight the therapeutic potential of targeting ERS pathways as a novel approach to cardiomyopathy treatment, offering a conceptual framework for future translational research and precision medicine strategies.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1577186"},"PeriodicalIF":2.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fast-track extubation in minimally invasive cardiac surgery: limits and lessons of a 4-year single-center analysis.","authors":"Sebastian Johannes Bauer, Moritz Benjamin Immohr, Friederike Irmgard Schoettler, Yukiharu Sugimura, Arash Mehdiani, Matthias Thielmann, Ajay Moza, Anna Fischbach, Michael Knapen, Evangelos Karasimos, Georg Eberhardt, Gereon Schaelte, Rolf Rossaint, Gernot Marx, Payam Akhyari","doi":"10.3389/fcvm.2025.1567533","DOIUrl":"10.3389/fcvm.2025.1567533","url":null,"abstract":"<p><strong>Background: </strong>Fast-track extubation is a key component of the interdisciplinary treatment concept Enhanced Recovery After Surgery (ERAS). In preparation for implementing ERAS as a comprehensive approach, we aimed to analyze the current state of fast-track extubation in the operating room, focusing on Minimally Invasive Cardiac Surgery (MICS). Specifically, we assessed the potential benefits of immediate on-table extubation compared to extubation within six hours after the completion of MICS.</p><p><strong>Methods: </strong>During a 4-year period from 2019-2023, a total of <i>n</i> = 146 patients underwent MICS at our institution. Surgical aspects were retrospectively analysed along with patients' risk profiles and relevant comorbidities. After 1:1 best neighbor propensity score matching, patients who were admitted to intensive care unit intubated but were extubated within six hours after surgery (fast-track, FT) were compared to those who were extubated in the operating room (extubation in tabula, EIT). The primary endpoint was fast-track failure (FTF), a composite of setbacks in the postoperative course: revision surgery, re-intubation, and readmission to ICU or intermediate care unit (IMC).</p><p><strong>Results: </strong>Patients had a median age of 61 years (IQR: 51.3-67.8) and were predominantly male (76.7%). The primary study endpoint occurred in 20.0% of all matched patients (FT: 26.7%, EIT: 13.3%; <i>p</i> = 0.289). FT patients had longer cardiopulmonary bypass times [FT 165.0 min (146.5-217.5); EIT 158.5 min (128.0-189.5); <i>p</i> = 0.047], but the duration of surgery was comparable. Additionally, the average length of hospital stay did not differ. A multivariate analysis was conducted and identified preoperative atrial fibrillation and intraoperative hypothermia as predictive risk factors for FTF.</p><p><strong>Conclusions: </strong>According to our retrospective single-center analysis, extubation in the operating room is feasible and safe even outside of a structured ERAS program. However, as itself it does not impact the further hospital stay, if there is no action thereafter, e.g., same day physiotherapy.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1567533"},"PeriodicalIF":2.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Experience of a case of cardiac arrest caused by postoperative pulmonary embolism and hepatic rupture induced by cardiopulmonary resuscitation.","authors":"Haowen Yang, Yuehong Li, Xiongbing Peng, Zhaojun Li, Peiwan Liu, Xingbao Fang","doi":"10.3389/fcvm.2025.1624064","DOIUrl":"10.3389/fcvm.2025.1624064","url":null,"abstract":"<p><p>Postoperative pulmonary embolism (PE) poses a serious threat to a patient's life. However, cases involving concurrent liver rupture are exceedingly rare. This report describes a case of a patient who experienced cardiac arrest due to PE following lower extremity varicose vein surgery, followed by liver rupture during cardiopulmonary resuscitation (CPR). Under the timely intervention of a multidisciplinary team (MDT), the patient underwent extracorporeal membrane oxygenation (ECMO)-assisted resuscitation and hepatic repair surgery. Through a staged anticoagulation strategy, a balance was achieved between bleeding control and thrombosis prevention. Ultimately, after 23 days of treatment, the patient regained consciousness and was transferred to rehabilitation.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1624064"},"PeriodicalIF":2.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent hemorrhage and thrombosis: a case report of hemoptysis from pulmonary vein stenosis with left ventricular thrombus.","authors":"Yingjie Chen, Wei Yu, Min Liu, Qunxiang Liu, Wei Qin, Ziyang Zhu, Shi Chen, Chenghong Li, Fajiu Li","doi":"10.3389/fcvm.2025.1666077","DOIUrl":"10.3389/fcvm.2025.1666077","url":null,"abstract":"<p><p>We report a rare case of concurrent pulmonary vein stenosis (PVS) and left ventricular thrombus (LVT) in a 46-year-old male with dilated cardiomyopathy and prior radiofrequency catheter ablation for atrial fibrillation, who presented with hemoptysis and dyspnea. Imaging confirmed left pulmonary vein occlusion and LVT, creating a therapeutic conflict between bleeding control and anticoagulation. We implemented a staged strategy: urgent balloon angioplasty and large-diameter bare-metal stent implantation to improve PVS hemodynamics and halt hemoptysis; subsequently, rivaroxaban and clopidogrel were initiated for LVT. At 6-month follow-up, symptoms resolved with complete LVT absorption, though LIPV developed in-stent re-occlusion. This demonstrated that prioritizing PVS intervention before anticoagulation effectively balances hemorrhage and thrombosis risks in this complex scenario.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1666077"},"PeriodicalIF":2.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional, and national burden of atrial fibrillation and flutter associated with metabolic risk factors, 1990-2021.","authors":"Lu Wang, Xinghua Qin, Linyan Jin, Haoyu Gong, Chong Gao, Hongtao Wang, Peng Liu","doi":"10.3389/fcvm.2025.1578908","DOIUrl":"10.3389/fcvm.2025.1578908","url":null,"abstract":"<p><strong>Objectives: </strong>Atrial fibrillation/flutter (AF/AFL) is increasingly correlated with metabolic risk factors. This study analyzed mortality, disability-adjusted life years (DALYs), annual percentage changes (APCs), and estimated annual percentage changes (EAPCs), stratified by age, sex, Socio-demographic Index (SDI), and region, to evaluate the global burden of AF/AFL linked to metabolic risk factors.</p><p><strong>Methods: </strong>Data on prevalence, incidence, mortality, DALYs, and age-standardized rates (ASRs) for AF/AFL associated with metabolic risk factors were extracted from the Global Burden of Disease (GBD) 2021 study. EAPCs were used to assess temporal trends in ASRs.</p><p><strong>Results: </strong>In 2021, metabolic risk factors were correlated with approximately 117,012 deaths and 2,881,800 DALYs globally due to AF/AFL, reflecting increases of 196.08% and 154.51%, respectively, compared to 1990. The burden varied considerably by sex, SDI, and region. Women, older adults, and high-SDI regions exhibited higher burdens, while men, younger individuals, and low-SDI regions showed more rapid increases.</p><p><strong>Conclusions: </strong>Metabolic risk factors are strongly correlated with the global burden of AF/AFL. Strengthening cost-effective interventions targeting these modifiable risks is essential-particularly in regions facing high or rapidly growing burdens.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1578908"},"PeriodicalIF":2.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145129882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The incidence of coronary in-stent restenosis and the rate of reaching the standard of low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and unstable angina pectoris treated with ezetimibe and rosuvastatin.","authors":"Fanhao Ye, Hao Chen, Hebo Li","doi":"10.3389/fcvm.2025.1599313","DOIUrl":"10.3389/fcvm.2025.1599313","url":null,"abstract":"<p><strong>Background: </strong>Diabetes is closely associated with the occurrence and development of coronary atherosclerotic heart disease. Coronary atherosclerosis is often severe and diffuse in patients with diabetes. We investigated the incidence of coronary in-stent restenosis (ISR) and the rate of reaching the standard of low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes mellitus (T2DM) and unstable angina pectoris (UAP) treated with ezetimibe and rosuvastatin one year later.</p><p><strong>Materials and methods: </strong>We selected the first pair of UAP patients with T2DM who underwent coronary artery stent implantation at our hospital between October 2018 and February 2022. According to drug use, the patients were divided into the rosuvastatin group [61 cases, rosuvastatin 10 mg/qn (every night)] and the combined group [60 cases, ezetimibe 10 mg/qd (once daily) and rosuvastatin 10 mg/qn]. Biochemical indices, left ventricular ejection fraction, and left ventricular end-diastolic diameter were collected before and one year after the first percutaneous coronary intervention. We collected data on the incidence of ISR and the rate of reaching the standard of LDL-C one year after surgery. Emergency PCI or coronary artery bypass grafting, cardiac death, and non-fatal acute myocardial infarction due to unstable angina pectoris 30 days after coronary stent implantation and lipid-lowering treatment were regarded as the primary endpoints.</p><p><strong>Results: </strong>After one year of follow-up, the incidence of in-stent restenosis(ISR), total cholesterol(TC), and LDL-C levels in the combined group[ISR, 3.33%; TC, 3.19 ± 0.75; LDL-C, 1.38(1.18-1.64)] were lower than those in the rosuvastatin group[ISR, 16.39% TC,C 3.84 ± 1.15; LDL-C, 1.92(1.52-2.61)] (<i>P</i> < 0.05). The rate of reaching the standard of LDL-C in the combined group (65%, 95% CI 0.560-0.809) was higher than that in the rosuvastatin group(31%, 95% CI 0.210-0.446) (<i>P</i> < 0.05). No significant difference in safety was observed between the two groups (<i>P</i> > 0.05). No endpoints were observed in the combined group.</p><p><strong>Conclusion: </strong>Resuvastatin combined with ezetimibe can better prevent ISR and reduce the incidence of cardiovascular adverse events. In addition, ezetimibe combined with rosuvastatin better reduced LDL-C levels.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1599313"},"PeriodicalIF":2.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12451000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Case reports in structural interventional cardiology: 2024.","authors":"Sunny Goel","doi":"10.3389/fcvm.2025.1681790","DOIUrl":"https://doi.org/10.3389/fcvm.2025.1681790","url":null,"abstract":"","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1681790"},"PeriodicalIF":2.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145112249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medicinal plants administered to control hypertension in Ethiopia: ethnomedicine, pharmacology, nutraceutical, phytochemistry, toxicology, and policy perspectives.","authors":"Dejen Nureye, Getnet Tadege, Silesh Dubale, Dereje Kebebe, Sultan Suleman, Elvine Pami Nguelefack-Mbuyo","doi":"10.3389/fcvm.2025.1514911","DOIUrl":"10.3389/fcvm.2025.1514911","url":null,"abstract":"<p><p>In traditional folk medicine, medicinal plants are widely employed. High blood pressure, a major cause of morbidity and mortality in healthcare settings, is linked to the risk of cardiovascular illnesses and many other serious health issues that can develop from it. This review provides background regarding hypertension, including introductory concepts, risk factors, and treatment approaches. Hypertension may not be effectively treated with the use of diuretics, ACE inhibitors, beta-blockers, alpha-blockers, calcium channel blockers, direct vasodilators, renin inhibitors, etc. These drugs' side effects include intolerance, weakened disease control, and improper therapy management. Therefore, an approach for extracting new therapeutic chemicals from medicinal plants is receiving attention today. As a result, this article provides a list of 85 plant species from 40 families, compiling data on ethnobotanical claims, plant parts used to make extracts, different types of extracts and study animals, nutracuticals' intended use, the antihypertensive effect of the extracts, their mode of action, clinical trials, toxicity profile, etc. It also mentions 55 specific chemical compounds that have shown potential to lower blood pressure in lab tests and live subjects, along with their dosage and how they work, based on online searches of published studies from different sources. Researchers looking into and developing new anti-hypertensive therapies to treat hypertension would benefit from our current work. We also tried to address the policy implications.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1514911"},"PeriodicalIF":2.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145112269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}